Bioelectronics Corp (BIEL)

[GetSeriousOK]

A perfect example of why Kelly Whelan is not qualified to be CEO of a publicly traded company.

That trial is double-blinded. And it's not completed yet.

https://clinicaltrials.gov/ct2/show/NCT05392803?term=PEMF&cond=phantom+pain&draw=2&rank=1

You can't release any kind of results from a trial being actively conducted unless it's stated in your protocol. This is Clinical Trial 101 and Kelly Whelan apparently skipped class that day.

In a trial this small (40 participants) this could skew the results if the other participants read that testimonial. I can only image what Dr. Ilfeld said when he saw that Whelan had published that testimonial.

Furthermore, the testimonial she published might have come from a placebo effect, depending on whether the participant had the sham device first or the active device. Whelan doesn't know which group the participant was in because Ilfeld won't unblind the results until the trial is completed.

A rookie move from our rookie CEO that could cause Ilfeld to throw his hands in the air and end the trial.